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halo2010@gmail.cAbstract Vesicular systems are a novel means of drug delivery that can enhance bioavailability of
encapsulated drug and provide therapeutic activity in a controlled manner for a prolonged period
of time. Liposomes were the ﬁrst such system but they suffer from a number of drawbacks
including high cost and lack of stability at various pHs. Niosomes are a nonionic surfactant
vesicular system, which can be easily and reliably made in the laboratory. Many factors affect
noisome formation such as the method of manufacture, nature of surfactant and encapsulated
drug, temperature at which the lipids are hydrated and the critical packing parameter. This review
describes all aspects of niosomes including their different compositions, the various methods of
preparation, the effect of changing manufacturing parameters, methods of characterization, factors
that affect their stability, their use by various routes of administration, their therapeutic
applications and the most important patents. The review also provides detailed information of
the various types of niosomes that provide effective drug delivery.
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Nonionic surfactant vesicular systems 2091. Introduction
Vesicles are colloidal particles in which a concentric bilayer
made-up of amphiphilic molecules surrounds an aqueous
compartment1–3. They are a useful vehicle for drug delivery
of both hydrophobic drugs, which associate with the lipid
bilayer and hydrophilic drugs, which are encapsulated in the
interior aqueous compartment. In general, vesicles made of
natural or synthetic phospholipids are called liposomes
whereas those made of nonionic surfactants (e.g. alkyl ethers
and alkyl esters) and cholesterol constitute a nonionic surfac-
tant vesicular system called niosomes3–5. Modiﬁed liposomal
systems include transferosomes that, besides phospholipids,
contain a single chain surfactant as an edge activator1,6–8 and
ethosomes that contain ethanol as an edge activator9. There
are also niosomes containing bile acids called bilosomes that
show enhanced stability in the presence of bile salts in the
gastrointestinal tract.
The composition of vesicles affects their physicochemical
characteristics such as their size, charge, lamellarity, elasticity
and thermodynamic phase. The vesicular structure can also be
modiﬁed to provide sustained or controlled drug delivery for
prolonged periods3,10,11. Liposomes can encapsulate a wide
variety of drugs such as many cytotoxic drugs, antimicrobial
drugs, proteins and genetic material12,13 and deliver them to the
target site. They have a number of advantages over other drug
delivery systems but also some disadvantages such as high cost
and limited shelf life due to the rancidiﬁcation of lipids14.
Niosomes (Fig. 1) are a very useful drug delivery system with
numerous applications as described below2,3,10,12,14.
Nonionic surfactants can improve the solubility of some
poorly soluble drugs15. Formulation in niosomes can also
improve their bioavailability as shown for acyclovir and
griseofulvin16,17. The stability of peptide drugs can be sig-
niﬁcantly increased by encapsulation in niosomes18. For
instance, insulin loaded niosomes have high resistance to
proteolytic enzymes and exhibit good stability in the presence
of sodium deoxycholate19. Transdermal delivery of various
drugs such as minoxidil, enoxacin, aceclofenac and estradiol
are enhanced by encapsulation in niosomes20–23. Finally
encapsulation in niosomes can provide sustained release of
drugs to prolong their duration of action. Examples include
estradiol and withaferin23,24. Similarly formulation of timolol
maleate in niosomes prepared using chitosan prolonged its
effect on intraocular tension25.Figure 1 Structure of a nonionic surfactant vesicle (niosome).2. Formulation aspects
It is necessary to understand the role of the basic structural
components of niosomes before preparation. These compo-
nents include the nonionic amphiphiles/surfactants and the
hydration medium.
2.1. Nonionic amphiphiles/surfactants
Nonionic surfactants are the most common type of surface
active agent used in preparing vesicles due to the superior
beneﬁts they impart with respect to stability, compatibility and
toxicity compared to their anionic, amphoteric or cationic
counterparts26–28. They are generally less toxic, less hemolytic
and less irritating to cellular surfaces and tend to maintain
near physiological pH in solution. They have many functions
including acting as solubilizers, wetting agents, emulsiﬁers
and permeability enhancers. They are also strong P-glycopro-
tein inhibitors, a property useful for enhancing drug absorp-
tion and for targeting to speciﬁc tissues29 as shown for
anticancer drugs such as doxorubicin and daunorubicin30,
steroids such as hydrocortisone and dexamethasone31, HIV
protease inhibitors such as ritonavir and saquinavir32,33,
cardiovascular drugs such as digoxin and quinidine34 and
beta-blockers such as acebutolol and timolol35.
Nonionic surfactants are comprised of both polar and non-
polar segments and possess high interfacial activity. The forma-
tion of bilayer vesicles instead of micelles is dependent on the
hydrophilic–lipophilic balance (HLB) of the surfactant, the
chemical structure of the components and the critical packing
parameter (CPP)3. On the basis of the CPP of a surfactant, the
type of vesicle, which it will form, can be predicted as shown in
Fig. 23. The method of calculating CPP from the volume of the
hydrophobic group, area of the hydrophilic head group and
length of the lipophilic alkyl chain of the surfactant is also
shown in Fig. 23.
The chain length and size of the hydrophilic head group of
the nonionic surfactant affect the entrapment efﬁciency of
drug. Nonionic surfactants with stearyl (C18) chains show
higher entrapment efﬁciency than those with lauryl (C12)
chains. The Tween series of surfactants bearing a long alkyl
chain and a large hydrophilic moiety in combination with
cholesterol in a 1:1 ratio have the highest entrapment efﬁ-
ciency of water soluble drugs3,4,36.
The HLB value of a surfactant plays a key role in controlling
drug entrapment of the vesicle it forms. A surfactant with anFigure 2 Critical packing parameter (CPP) of an amphiphile where
n is the hydrophobic group volume, lc the critical hydrophobic group
length and a0 the area of the hydrophilic head group.
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niosomes whereas one with an HLB value of 8.6 gives niosomes
with the highest entrapment efﬁciency. Entrapment efﬁciency
decreases as the HLB value decreases from 8.6 to 1.737–39.
For HLB46, cholesterol must be added to the surfactant in
order to form a bilayered vesicle37 and for lower HLB values,
cholesterol enhances stability of vesicles. It is also seen that the
addition of cholesterol enables more hydrophobic surfactants to
form vesicles, suppresses the tendency of the surfactant to form
aggregates, and provides greater stability to the lipid bilayer by
promoting the gel liquid transition temperature of the vesicle37.
The entrapment efﬁciency is affected by the phase transition
temperature (Tc) of the surfactant. Thus Span 60 with a high Tc
exhibits the highest entrapment efﬁciency38. The most common
nonionic amphiphiles used for vesicle formation are alkyl ethers,
alkyl esters, alkyl amides and esters of fatty acids3.
2.1.1. Alkyl ethers and alkyl glyceryl ethers
Alkyl ethers are good vesicle forming nonionic surfactants.
They are stable, relatively non-irritant to the skin and
compatible with other surfactants40. Due to their high stability
they can be used to encapsulate proteins and peptides
although it was shown that their encapsulation capacity is
reduced when combined with cholesterol19.
2.1.1.1. Polyoxyethelene 4 lauryl ether (Brij 30). This surfac-
tant has an HLB value of 9.7 and a phase transition
temperature o10 1C41,42. Unlike other alkyl ether derivatives,
which reduce vesicle formation in the presence of cholesterol,
Brij 30 forms large unilamellar vesicles when combined with
30 mmol/L cholesterol. However, it cannot be used to for-
mulate some drugs and iodides, mercury salts, phenolic
substances, salicylates, sulfonamides and tannins. Polyox-
yethylene alkyl ethers are also incompatible with benzocaine,
tretinoin and oxidizable drugs since, with such substances, it
causes oxidation leading to discoloration of product41,42.
However, Manconi et al.43,44 prepared niosomes of tretinion
using polyoxythelene 4 lauryl ether and reported that
it formed large unilamellar vesicles with high entrapment
efﬁciency.
2.1.1.2. Polyoxyethylene cetyl ethers (Brij 58). Brij 52, 56
and 58 are cetyl derivatives of polyoxyethylene with vesicle
forming capability. Among them, Brij 58 has got special
importance due to its ability to form inverted vesicles, which
are useful for studying ion-pumping activity (Hþ-ATPase and
Ca2þ-ATPase) at the plasma membrane. This ability is the
result of ‘non-detergent behavior’ associated with its large
head group (E20-23)45. Brij 58 is commercially available under
a variety of trade names including poly(oxyethylene) cetyl
ether, Brij W1, polyethylene oxide hexadecyl ether, polyethy-
lene glycol cetyl ether, Brij 38, Brij 52, poly(oxyethylene)
palmityl ether, Brij 56, Atlas G 3802, cetocire, cetyl alcohol
ethoxylate, Nikkol BC 40, etc. The HLB value of Brij 58
is 15.741.
2.1.1.3. Polyoxyethylene stearyl ethers (Brij 72 and 76). They
are stearyl derivatives of polyoxyethylene ether with good
vesicle forming properties. In particular, Brij 72 forms multi-
lamellar vesicles with high encapsulation efﬁciency. Thus,
vesicles made of Brij 72 encapsulated more ﬁnasteride than
those formulated using Brij 7646. This is probably because ofits low HLB value of 4.9 compared to that of Brij 76 of 12.441.
Chloramphenicol sodium succinate loaded Brij 72 niosomes
have also found application in intracellular chemotherapy47.
However, higher drug entrapment of minoxidil was reported
in vesicles prepared using Brij 7622.2.1.2. Sorbitan fatty acid esters
These derivatives of polyoxyethylene esters are often used in
cosmetics to solubilize essential oils in water-based products.
Esters of plain (non-PEG-ylated) sorbitan with fatty acids are
usually referred to as Spans. Their gel transition temperature
increases as the length of the acyl chain increases. Thus
sorbitan monolaurate (Span 20) with a C9 chain is liquid at
room temperature; sorbitan monopalmitate (Span 40) with a
C13 chain has a gel transition temperature of 46–47 1C;
sorbitan monostearate (Span 60) with a C15 chain has a gel
transition temperature of 56–58 1C. Vesicles made with these
higher molecular weight Spans are less leaky and more stable
to osmotic gradients5.
The molar ratio of cholesterol to Span may affect the
entrapment of drugs into niosomes. Thus higher encapsulation
of acyclovir was reported in niosomes made using a cholesterol:
Span 80 ratio of 1:310 although high encapsulation of colchicine
and 5-ﬂourouracil was reported in niosomes made with a
cholesterol:Span ratio of 1:148. Fang et al.21 reported Span 40
was required in a proniosomal formulation of estradiol to
enhance its permeation across the skin. A decrease in entrapment
efﬁciency of retinyl palmitate was reported as the length of the
lipophilic chain increased in the order Span 404Span 604Span
8549. In developing niosomes for ocular delivery of acetazolamide,
Ahmed et al.50 found Span 60 formed multilamellar vesicles with
high encapsulation efﬁciency.2.1.3. Polyoxyethylene fatty acid esters
Polysorbates are liquids derived from PEG-ylated sorbitan
esteriﬁed with fatty acids. The distribution of zidovudine after
an intravenous bolus injection of niosomes prepared using
Tween 80 to mice was seen in lungs, kidney, heart, liver and
spleen and was comparatively higher than from niosomes
made using dicetyl phosphate or Tween 8051. The slow release
of paclitaxel from Tween 28 niosomes was beneﬁcial in
reducing its toxic side effects52.2.2. Hydration medium
Phosphate buffer at various pHs is the most commonly used
hydration medium for preparation of niosomes. The actual
pH of the hydration medium depends on the solubility of the
drug being encapsulated3. Thus pH 5.5 phosphate buffer was
used in the preparation of ketoconazole niosomes53 whereas
pH 7.4 phosphate buffer was used in the preparation of
meloxicam niosomes54.3. Methods of preparation
The general method of preparation of niosomes involves
evaporation to produce a lipid ﬁlm followed by hydration
with the hydration medium. However, there are variants of
this method that are described here in detail.
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Equal proportions of surfactant and cholesterol are dissolved
in chloroform and evaporated under reduced pressure to
produce a thin lipid ﬁlm on the wall of a round-bottomed
ﬂask. The ﬁlm is hydrated with a solution of an acidic
compound (generally citric acid) by vortex mixing. The
resulting product is subjected to freeze-thaw cycles after which
an aqueous solution of drug is added and the mixture
vortexed. The pH of the sample is then raised to 7–7.2 using
a disodium hydrogen phosphate solution55,56. Bhaskaran and
Lakshmi11 prepared niosomes using this method and reported
an entrapment efﬁciency of 87.5%.3.2. Lipid layer hydration
The thin ﬁlm, prepared as described above, is hydrated with
an aqueous solution of drug at a temperature slightly above
the phase transition temperature of the surfactants for a
speciﬁed time with constant mild shaking11,55–59. Process
variables to be validated include the mass per batch, angle
of evaporation and rotation speed of the vacuum rotary
evaporator and the hydration process. The latter is developed
by varying the solvent (water, phosphate buffer (PB) and PB/
drug) and hydration temperature below and above the gel
transition temperature. Using thin ﬁlm hydration under
reduced pressure, Sathali and Rajalakshmi60 developed multi-
lamellar vesicles containing terbinaﬁne which, upon sonica-
tion, produced small unilamellar niosomes with an entrapment
efﬁciency of about 85%. Bhaskaran and Lakshmi11 reported
that about 78% of the drug was entrapped in the aqueous
compartment of niosomes which was prepared using the hand
shaking process.3.3. Reversed phase evaporation
The surfactants are dissolved in a mixture of ether and
chloroform to which an aqueous phase containing the drug
is added. The resulting two-phase system is then homogenized
and the organic phase evaporated under reduced pressure to
form niosomes dispersed in the aqueous phase11. Spherical
stable uniform vesicles containing lansoprazole were prepared
using this method61. Guinedi et al.50 also used this method to
develop niosomes containing acetazolamide and reported that
spherical vesicles were produced with less drug entrapment
than in multilamellar vesicles. Gyanendra et al.62 developed
isoniazid niosomes by reversed phase evaporation.3.4. Microﬂuidization
Microﬂuidization is the process where a solution of surfac-
tants and drug is pumped under pressure from a reservoir
through an interaction chamber packed in ice at a rate of
100 mL/min. From the interaction chamber, the solution is
passed through a cooling loop to remove the heat produced
during microﬂuidization and returned to the reservoir for
recirculation or allowed to exit the system. The process is
repeated until a vesicle of the desired size is produced63,64.3.5. Ether injection
In this method, the lipids and drug are dissolved in diethyl
ether and injected slowly into an aqueous phase, which is
heated above the boiling point of the organic solvent. This
produces large unilamellar vesicles, which are further sub-
jected to size reduction3,11,57. Bhaskaran and Lakshmi11
prepared salbutamol niosomes by ether injection with an
entrapment efﬁciency of 67.7%.
3.6. Bubbling of nitrogen
In this method nitrogen gas is passed through a sample of
homogenized surfactants to give large unilamellar vesicles.
These are then subjected to size reduction to give small
unilamellar vesicles65.
3.7. The Handjani–Vila method
Here a homogeneous lamellar phase is produced by mixing a
lipid or lipid mixture with an aqueous solution containing an
equivalent amount of active substance. The resultant mixture
is homogenized at a controlled temperature by means of
ultracentrifugation or agitation66.
3.8. The enzymatic method
Niosomes may also be formed by an enzymatic process from a
mixed micellar solution. In this method ester links are cleaved
by esterases leading to breakdown products such as choles-
terol and polyoxyethylene, which in combination with dicetyl
phosphate and other lipids produce multilamellar niosomes.
The surfactants used are polyoxyethylene stearyl derivatives
and polyoxyethylene cholesteryl sebacetate diacetate3.
3.9. The single pass technique
This is a patented technique involving a continuous process
that comprises the extrusion of a solution or suspension of
lipids through a porous device and subsequently through a
nozzle. It combines homogenization and high pressure extru-
sion to produce niosomes with a narrow size distribution in
the range 50–500 nm67.4. Factors affecting niosome formation
4.1. Effect of cholesterol
Cholesterol inﬂuences the physical properties and structure of
niosomes possibly due to its interaction with the nonionic
surfactants68. The interaction is of biological interest since
cholesterol is always present in biological membranes where
it inﬂuences membrane properties such as aggregation, ion
permeability, fusion processes, elasticity, enzymatic activity, size
and shape68. The effect of cholesterol in lipid bilayers is mostly
to modulate their cohesion and mechanical strength and their
permeability to water4,68,69. Through the addition of cholesterol,
the ﬂuidity of niosomes is changed considerably68. Cholesterol
imparts rigidity to vesicles, which is very important under severe
stress conditions70. The interaction of cholesterol with Span 60
Figure 3 Structural interaction between Span 60 and cholesterol.
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in Fig. 3.
The amount of cholesterol to be added depends on the HLB
value of the surfactants. As the HLB value increases above 10,
it is necessary to increase the minimum amount of cholesterol
to be added in order to compensate for the larger head
groups3. Higher entrapment of minoxidil occurred in Brij 76
niosomes in the presence of a higher content of cholesterol
whereas no signiﬁcant increase in entrapment efﬁciency
occurred in Brij 52 (HLB 5.3) niosomes. In fact, above a
certain level of cholesterol, entrapment efﬁciency decreased22
possibly due to a decrease in volume diameter (CPPo0.05)19.
4.2. Nonionic surfactant structure
Vesicle aggregation of niosomes may be prevented by the
inclusion of compounds that introduce repulsive steric or
electrostatic forces. An example of steric stabilization is the
inclusion of Solulan C24 (a cholesteryl poly-24-oxyethylene
ether) in doxorubicin sorbitan monostearate (Span 60) nio-
some formulations. Examples of electrostatic stabilization are
the inclusion of dicetyl phosphate in 5(6)-carboxyﬂuorescein
loaded Span 60 based niosomes and the inclusion of stearyl
amine in rifampicin loaded niosomes3.
4.3. Surfactant and lipid amount
The maximum amount of surfactant/lipid used to prepare
niosomes is generally 10–30 mmol/L (1–2.5%, w/w). Altera-
tions in the surfactant:water ratio during the hydration step
may affect the structure and properties of the niosomes
produced. As the surfactant/lipid level increases, the amount
of drug to be encapsulated also increases leading to an
increase in the viscosity of the system3.
4.4. Effect of encapsulated drug
Another factor to be considered is whether the drug to be
encapsulated is amphiphilic. The best example of such a drug
is doxorubicin. When encapsulated in niosomes, aggregation
occurred and was overcome by the addition of a steric
stabilizer30. The increase in encapsulation of a drug that
occurs when more is added could be the result of saturationof the medium. This suggests that the solubility of certain
poorly soluble drugs can be increased by formulation in
niosomes but only up to a certain limit above which drug
precipitation will occur22. An increase in the encapsulation of
ﬂurbiprofen due to saturation of drug in the hydration
medium has been reported71. However, when niosomes were
prepared using higher amounts of minoxidil, optical micro-
scopy revealed minoxidil crystals dispersed in between the
niosomal particles22.4.5. Effect of temperature
Temperature of the hydration medium plays a major role in
the formation of vesicles and affects their shape and size. The
temperature should always be above the gel to liquid phase
transition temperature of the system. Temperature affects the
assembly of surfactants into vesicles and also induces changes
in vesicle shape3,68. For example, polyhedral vesicles formed
by C16:solulan C24 (91:9) at 25 1C transformed into spherical
vesicles upon heating to 48 1C but, on cooling from 55 1C,
formed a cluster of smaller spherical niosomes at 49 1C and
changed to a polyhedral structure at 35 1C. In contrast,
vesicles formed by C16:cholesterol:solulan C24 (49:49:2)
showed no shape transformations on heating or cooling36.
Volume of the hydration medium and duration of hydration
of the lipid ﬁlm also affect vesicle structure and yield68.4.6. Effect of pH of the hydration medium
Entrapment efﬁciency of niosomes is greatly affected by the
pH of the hydration medium. High entrapment of ﬂurbiprofen
was reported at acidic pH with a maximum encapsulation
efﬁciency of 94.6% at pH 5.5. The fraction of ﬂurbiprofen
encapsulated increased to about 1.5 times as pH decreased
from 8 to 5.5 and decreased signiﬁcantly at pH46.8. The
lowest entrapment of ﬂurbiprofen occurred at pH 7.4 and 8
with no signiﬁcant difference between them. The increase in
encapsulation efﬁciency of ﬂurbiprofen at lower pH is pre-
sumably due to its ionizable carboxylic acid group. At lower
pH, the proportion of unionized ﬂurbiprofen increases and
partitions more readily into the lipid bilayer than the ionized
species71. At lower pH, niosome formulations should be
examined by optical microscopy for the presence of drug
precipitates both before and after centrifugation and washing.
This will help to determine the concentration of drug in the
hydration medium giving optimum encapsulation in niosomes.5. Characterization
Vesicle structure and shape can be characterized by various
types of microscopy such as optical12, freeze fracture elec-
tron72, surface electron, scanning electron, negative staining
transmission electron, cryo-electron, ﬂuorescence and confo-
cal73. The interfacial surface tension of a vesicular system
determines the structure of the supramolecular elements of
multilamellar vesicles74.
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Size and charge of vesicles have a signiﬁcant effect on their
stability and drug encapsulation. Size and charge can be
assessed using a multifunctional zeta potential analyzer11
where size of vesicles is the result of repulsion forces between
the bilayers and the entrapped drug. Manosroi et al.75 found
that the size of niosomes loaded with gallidermin was smaller
for anionic niosomes than cationic niosomes due to neutrali-
zation of their negative charge by the positive charge of
entrapped gallidermin. Correspondingly, cationic niosomes
were larger due to repulsion between the positive charges of
the niosomes and gallidermin.5.2. Entrapment efﬁciency
This is determined by measuring the difference between the
unentrapped and total amounts of drug. Unentrapped drug is
determined by various techniques such as exhaustive dialy-
sis57, gel ﬁltration6,7,46 and centrifugation3. Total amount of
drug can be determined by digesting a speciﬁc amount of a
preparation and analyzing with a suitable analytical method.
Percent entrapment can then be calculated in the usual way76.5.3. In vitro release
In-vitro release studies are carried out by dialysis through a
semipermeable membrane. A niosome preparation is incorpo-
rated in an open end dialysis membrane and placed in a
receptor compartment containing buffer. Samples are peri-
odically collected and analyzed using a suitable analytical
method55,75,76. Alternatively Hu’s method can be used77,78.6. Stability
The main problems associated with storage of vesicles are
aggregation, fusion and leakage of drug. Ammar et al.79
deﬁned stable formulations of tenoxicam as those showing
high entrapment efﬁciency (460%) and retention (490%)
over a period of months. At the end of each month, only
stable formulations were selected to continue for another
month. It was found that there was no signiﬁcant change in
the mean size of vesicles after 90 days when compared with
those of freshly prepared sucrose stearate niosomes. However,
the entrapment efﬁciency was affected (10%) following
storage80.
The stability of niosomes is also assessed under conditions,
which promote photodegradation such as exposure to UV
irradiation and ﬂuorescent light43. For the former, drug is
analyzed after the drug solution and vesicle preparation are
maintained at room temperature and exposed to UV radiation
for 1 h at 25 1C. Such studies have been reported for niosomes
loaded with tretinoin, a metabolite of vitamin A43. For the
latter, the samples are exposed to artiﬁcial light at room
temperature for a speciﬁc period and the drug concentration
determined81.7. Delivery strategies
The administration of niosomes by various routes has been
reported and it is clear that the route is important in designing
a vesicular formulation. For example, enoxacin, a ﬂuoroqui-
nolone antibiotic with a broad spectrum of activity, has a
plasma half-life after oral administration of only 3–6 h such
that frequent dosing is necessary for effective antibiotic
therapy. Subsequently, the oral formulation was withdrawn
due to a high frequency of drug interactions and adverse
effects20 and a transdermal delivery system based on niosomes
was developed. This is now the preferred formulation because
it reduces the adverse effects of oral administration and
provides a long duration of action20.7.1. Oral route
The oral route is generally preferred leading to a research
emphasis on delivery of niosomes via the oral route.
A niosome formulation of acyclovir providing a Higuchi pattern
of drug release was found to enhance sustained release of drug
in an in vivo study in rabbits. In this study, the oral bioavail-
ability and MRT of acyclovir were increased more than 2-fold
compared to a tablet dosage form. Similarly, a Span 60 niosome
formulation of ﬂuconazole with an encapsulation efﬁ-
ciency491% showed sustained release by zero order followed
by ﬁrst order kinetics82. Griseofulvin loaded niosomes have been
subjected to an in vitro–in vivo correlation study, which showed
that niosomes were an efﬁcient way to enhance the bioavail-
ability and sustained delivery of griseofulvin via the oral route17.
These studies all indicate that niosomes are a promising delivery
systems for sustained drug release16. However, the main obsta-
cles to oral delivery are hepatic ﬁrst pass metabolism and GI
irritation, limitations that can be overcome using other routes of
administration. For oral immunization, mannosylated nonionic
surfactant based vesicles have been developed for the efﬁcient
delivery of plasmid DNA encoding small subunit proteins of
hepatitis B virus. Rifampicin and gatiﬂoxacin loaded niosomes
were effective against the tubercle bacilli for prolonged periods
and were better than the conventional dosage form because of
the reduced dose and greater patient compliance83.7.2. Topical route
7.2.1. Ocular delivery
The penetration of drug molecules into the eye depends on the
physicochemical properties of both the drug and vehicle6.
Vesicular systems provide prolonged duration of action at the
corneal surface by preventing ocular metabolism by enzymes
in the lachrymal ﬂuid84,85. Because of this, niosomes have
gained popularity in ocular drug delivery research and are a
potential delivery system for the effective treatment of glau-
coma86 and various other conditions. Allam et al.84 reported
that acyclovir loaded niosomes were effective for the treatment
of herpes simplex keratitis, a condition that can lead to
blindness. Similarly, gentamicin loaded niosomes provided
controlled, opthalmic delivery87 and brimonidine loaded nio-
somes were therapeutically effective with a long duration of
action due to slow and prolonged zero order release of drug88.
Bioavailability of oﬂoxacin in the eye was improved to
Gannu P. Kumar, Pogaku Rajeshwarrao21473.8%89 and niosomes promoted ocular absorption of cyclo-
pentolate, which is essential in pediatric eye examinations90.
7.2.2. Transdermal delivery
The major obstacle to topical delivery of drugs is the barrier
function of the stratum corneum. Vesicular delivery through
the skin is advantageous in that drugs, which permeate
through the skin reach the systemic circulation. Niosomes
are the best vesicular system for transdermal delivery because
they act as a reservoir of drug for a prolonged period of time
and enhance skin penetration. Thus estradiol loaded niosomes
made with the inclusion of cholesterol facilitated estradiol
transdermal permeation21. A high cumulative drug penetra-
tion and steady state transdermal ﬂux was observed from an
aceclofenac niosomal gel preparation compared to a plain gel
formulation23. Similarly a meloxicam niosomal gel produced a
greater reduction in edema in albino rats when compared to
the conventional meloxicam gel due to the penetration of
niosomes into the deeper layers of the skin54.8. Types of niosomes
Many types of niosomes are mentioned in the literature
including discomes, proniosomes, elastic niosomes and surfac-
tant ethosomes.
8.1. Proniosomes
Proniosomes are dry niosomes, which are hydrated immediately
before use to yield an aqueous niosome dispersion. Being dry,
they reduce problems associated with the physical stability of
niosomes such as aggregation, fusion and leaking and, in
addition offer beneﬁts in terms of transportation, distribution,
storage and dosing. Proniosomes, hydrated by agitation in an
aqueous phase for a short period of time, offer a versatile
vesicular delivery system with the potential for drug delivery via
the transdermal route91,92. This involves the topical application
of proniosomes under occlusive conditions during which they
are converted to niosomes due to hydration by water in the skin
itself. Compared to niosomes, a proniosome gel appeared to
deliver estradiol efﬁciently by the transdermal route21. Similarly
a niosomal gel containing ketoprofen was therapeutically super-
ior to a plain ketoprofen gel93. Proniosomal gel preparations of
contraceptive hormones such as estradiol, ethinyl estradiol and
levonorgestrel may also be useful for population control
programmes21,76,94. Proniosomes allow the nebulized delivery
of cromolyn sodium and provide enhanced controlled drug
release and physical stability80.
8.2. Surfactant ethosomes
Touitou et al.95 were the ﬁrst to prepare ethosomes, a lipid
vesicular system incorporating ethanol at relatively high con-
centrations. Ethosomes contain nonionic surfactants, a high
concentration of ethanol or isopropyl alcohol and water. Unlike
other vesicular systems, surfactant ethosomes were shown
to permeate through the stratum corneum and possess signiﬁ-
cantly higher transdermal ﬂux in comparison to liposomes
or nisosmes95. The exact mechanism by which they enhance
permeation into deeper skin layers remains unclear. Thesynergistic effect of the nonionic surfactant and high concentra-
tion of ethanol is suggested to be responsible for this deeper
distribution and penetration in skin lipid bilayers91,92,95–99.
8.3. Elastic niosomes
Elastic niosomes are composed of nonionic surfactants,
ethanol and water. They are superior to conventional nio-
somes because they enhance penetration of a drug through
intact skin by passing through pores in the stratum corneum,
which are smaller than the vesicles. In fact, their elasticity
allows them to pass through channels that are less than one-
tenth of their own diameter8,9. Thus they can deliver drugs or
compounds of both low and high molecular weight. Further-
more, they can provide prolonged action and demonstrate
superior biological activity compared to conventional nio-
somes100. The transport of these elastic vesicles is concentra-
tion independent and driven by trans-epidermal
hydration1,100,101. Van den Bergh et al.100,101 developed the
ﬁrst detergent-based elastic nanovesicles called elastic or
deformable niosomes consisting of surfactant L-595 (sucrose
laurate ester) and the micelle forming surfactant PEG-8-L
(octaoxyethylene laurate ester). Manosroi et al.102 developed
topical diclofenac diethylammonium loaded elastic niosomes
and reported high transdermal ﬂux in rat and high antiin-
ﬂammatory activity in the rat ear edema assay.
8.4. Discomes
These are the large discoid structures, which exist under certain
conditions of the phase diagram of nonionic surfactant vesicles.
Uchebu et al.103 prepared niosomes from hexadecyl diglycerol
ether (C16), cholesterol and dicetyl phosphate by mechanical
shaking and sonication followed by incubation with soluble
polyoxyethylene cholesteryl ether, Solulan C24, at 74 1C. A
partial phase diagram was constructed for the system in which
four phases could be identiﬁed; a lamellar phase, a micellar
phase, an uncharacterized phase, and a novel phase, which they
called the ‘discome’ phase. Vesicles in the discome phase were
large (volume distribution mean diameter 12–60 mm) and slowly
increased in size immediately after sonication. Discomes were
shown to entrap water soluble solutes102. Discomes of 5(6)-
carboxyﬂuorescein (CF) were developed and were found to
retain 50% of entrapped CF over a 24 h period at room
temperature.103 The drug delivery potential of discomes in the
ﬁeld of ophthalmology was highlighted by Vyas et al.25 who
reported that timolol maleate discomes gave a threefold increase
in ocular absorption of timolol compared to a solution.9. Therapeutic applications of niosomes
Niosomes are a versatile drug delivery system with many
pharmaceutical applications. Some of them are described below.
9.1. Pulmonary delivery
Inhalation therapy is frequently used in asthmatic patients but
is limited by poor permeation of drug through hydrophilic
mucus. To overcome this, Terzano et al.104 developed poly-
sorbate 20 niosomes containing beclomethasone dipropionate
Nonionic surfactant vesicular systems 215for pulmonary delivery to patients with chronic obstructive
pulmonary disease. They reported that the niosomes provided
sustained and targeted delivery, improved mucus permeation
and ampliﬁed therapeutic effect.
9.2. Protein and peptide delivery
The delivery of proteins to the systemic circulation after their oral
administration is hindered by numerous barriers including pro-
teolytic enzymes, pH gradients and low epithelial permeability.
The oral administration of recombinant human insulin in a
niosomal formulation was demonstrated in a study involving
niosomes based on polyoxyethylene alkyl ethers. Entrapment of
insulin in the bilayer structure of niosomes was shown to protect
it against proteolytic activity of a-chymotrypsin, trypsin and
pepsin in vitro. Even higher protection was provided by Brij
92/cholesterol niosomes in which only about 26% of entrapped
insulin was released over 24 h in simulated intestinal ﬂuid19. The
kinetics of drug release was described by the Baker and Lonsdale
equation indicating a diffusion based delivery mechanism. These
results suggest that niosomes can be developed as sustained release
oral dosage forms for delivery of peptides and proteins19,105.
Vasoactive intestinal peptide (VIP) has diverse therapeutic
applications because of its antiinﬂammatory and immunomo-
dulatory effects and its ability to regulate cell growth and
differentiation and participate in the development of neural
tissue18. VIP has been tested in the treatment of Alzheimer’s
disease but, like most endogenous peptides, its therapeutic
potential is limited by its failure to cross the blood–brain
barrier (BBB) and by its rapid elimination after intravenous
administration106. Dufes et al.105 reported glucose-bearing
niosomes encapsulating VIP for delivery to speciﬁc brain
areas105. They concluded that glucose-bearing vesicles repre-
sent a novel tool to deliver drugs across the BBB.
9.3. Cancer chemotherapy
Niosomes are an effective means of targeting delivery of
anticancer drugs to tumors. Paolino et al.107 developed bola
surfactant niosomes containing 5-ﬂuorouracil to treat skin
cancer. They reported enhanced drug penetration compared to
an aqueous solution of drug and to a suspension of empty
bola-niosomes in an aqueous solution of drug. Niosomes of
doxorubicin prepared from C16 monoalkyl glycerol ether with
and without cholesterol were reported by Uchegbu et al.108.
Compared to simple drug solution, methotrexate loaded
niosomes produced increased antitumor activity against
tumors in serum and lung but not in liver and spleen109.
9.4. Carrier for hemoglobin
Niosomes can be used as a carrier for hemoglobin. Vesicles were
permeable to oxygen and could be modiﬁed to produce a
hemoglobin dissociation curve similar to that of non-encapsu-
lated hemoglobin110. In addition, a niosomal suspension showed
a visible spectrum superimposable onto that of free hemoglobin.
9.5. Treatment of HIV-AIDS
Zidovudine is commonly used to treat patients with AIDS but
is limited by its toxicity and low potency. A noisomeformulation that may overcome these drawbacks has been
proposed by Ruckmani and Sankar111. They concluded that
zidovudine loaded niosomes would provide sustained delivery
of drug and a more effective AIDS therapy.9.6. Vaccine and antigen delivery
A number of surfactants have immunostimulatory properties112
and have been used as vaccine adjuvants. The adjuvanticity of
niosomes prepared from 1-monopalmitoyl glycerol: cholesterol:
dicetyl phosphate (5:4:1) was demonstrated in mice administered
a subcutaneous injection of ovalbumin or a synthetic peptide
containing a known T-cell epitope113 and bovine serum albu-
min114. Intraperitoneal administration of the same niosome
formulation was also shown to act as a vaccine adjuvant in
immune reconstituted SCID-human mice115.9.7. Transdermal delivery
Transdermal delivery of NSAIDs is the best way to avoid gastric
disturbances. Transferosomes and elastic niosomes are novel
types of vesicles for transdermal delivery116 with the latter having
the advantage of low cost of manufacturing. Manosroi et al.102
reported novel elastic niosomes containing diclofenac diethylam-
monium for topical use and concluded that they illustrated the
promise of such formulations of NSAIDs for topical non-invasive
treatment of inﬂammation. Srikanth et al.54 developed a melox-
icam niosomal gel and studied its antiinﬂammatory activity in the
carrageenan induced rat paw method. They concluded that the
niosomal gel was superior to a conventional gel formulation
because of the ability of niosomes to penetrate into the deeper
layers of the skin. However, for transdermal delivery of other
drugs, penetration of niosomes into the deeper layers of the
skin remains a problem. Hopefully, the design of elastic noisome
formulations will extend the application of this route of drug
delivery117.10. Conclusion
Nonionic surfactant vesicular systems, otherwise known as
niosomes, are a novel and efﬁcient approach to drug delivery.
Their vesicular membrane is mainly composed of nonionic
surfactants and cholesterol and the enclosed interior usually
contains a buffer solution at appropriate pH. Niosomes may
be prepared by various methods, which affect their formations
along with the properties of the drug, cholesterol content and
amount, structrue and type of surfactant. As a drug delivery
device, niosomes are osmotically active and stable. They also
improve the stability of the entrapped drug during delivery.
They do not require special conditions for handling, protec-
tion, storage or industrial manufacturing. In addition, they
can be prepared with different structural characteristics
(composition, ﬂuidity and size), and can be designed for
particular routes of administration. Overall, niosomes are a
very effective tool for drug delivery and targeting of numerous
therapeutically active moieties. They have the potential to
provide better treatment than conventional drug delivery
systems.
Table 1 Important patents related to niosomes.
Patent publication
number
Inventors Title Patent description in brief References
US2010/0068264 A1 Norma Alclantar, Eva C
Williams and Ryan Toomey
Niosome hydro gel drug
delivery
Drug encapsulated in
niosomes made of a
biodegradable polymer with a
temperature and pH-sensitive
hydro gel network (cross
linked chitosan) providing
controlled release of drug
118
US2010/0226932 A1 Gail Smith, Dinesh B. Shenoy
and Robert W. Lee
Adjuvant and vaccine
compositions
Addition of aluminum salts;
encapsulation in niosomes
improves the stability of




US2008/0050445 A1 Norma Alclantar, Kristina
Dearborn, Michael Van
Aukar, Ryan Toomey and
Elizabeth Hood
Niosome hydro gel drug
delivery
Drug encapsulated in
niosomes made of a
biodegradable polymer hydro
gel network providing a two-
fold increase in controlled
release rate
120
US2006/0292211 A1 Elizabeth Hood, Joel A.
Strom and Michael Van Aukar
Ultrasound enhancement of
drug release across nonionic
surfactant membranes
Ultrasound enhances the
delivery of drug encapsulated
in niosomes when given non-
invasively by altering the
niosome membrane structure
121
US2007/0172520 A1 Michael Van Aukar, Anna
Plaas and Elizabeth Hood
Immuno targeting of nonionic
surfactant vesicles
Niosomes provide targeted
delivery of antigens to the host
by retaining the bioactive
agent in the cytoplasm of
target cells
122
US2005/0239747 A1 Chih-Chiyang Yang, Yuan-
Chih le and Chao-Cheng Liu
Compositions and methods of
enhanced transdermal delivery
of steroidal compounds and
preparation methods
Niosomes are a delivery
system that increases
permeation of steroidal drugs
across dermal tissue
123
Gannu P. Kumar, Pogaku Rajeshwarrao21611. Patents
Because niosomes are becoming increasingly popular for
clinical use, the number of patents for niosomal formulations
is increasing enormously. A short summary of some of the
important patents pertaining to the encapsulation of various
drugs in niosomes is indicated in Table 1.
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